Continuing Medical Education: Vulvovaginal Atrophy: Current and Future Therapies (CME)
Article first published online: 1 MAR 2010
© 2010 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 7, Issue 3, pages 1042–1050, March 2010
How to Cite
Ibe, C. and Simon, J. A. (2010), Continuing Medical Education: Vulvovaginal Atrophy: Current and Future Therapies (CME). Journal of Sexual Medicine, 7: 1042–1050. doi: 10.1111/j.1743-6109.2009.01692.x
- Issue published online: 1 MAR 2010
- Article first published online: 1 MAR 2010
- Vaginal Atrophy;
- Vulvar Atrophy;
- Menopausal Symptoms;
- Post-Menopausal Urogenital Atrophy
Introduction. Vulvovaginal atrophy results from estrogen deficiency and affects a large number of postmenopausal women. Symptoms include vaginal dryness, itching, irritation, and dyspareunia.
Aim. The purpose of this review is to evaluate the efficacy, safety and acceptability of current treatment methods for vulvovaginal atrophy, as well as highlight evolving new treatment methods.
Method. We conducted a review of the literature concerning treatment of vulvovaginal atrophy.
Results. All currently available low-dose local estrogen formulations are effective and yield few side effects. Fears sparked by the Women's Health Initiative, as well as recommendations by the FDA, have generated interest in the development of new treatment methods. Lower doses of existing formulations have proven to be efficacious. The use of estrogen agonists/antagonists and intravaginal dehydroepiandrosterone (DHEA) have both been shown to positively affect vaginal atrophy symptoms without inducing endometrial proliferation.
Conclusion. Potential new treatment methods show promise to provide efficacy in treatment while avoiding unwanted side effects. Further research is needed to establish optimal treatment formulations. Ibe C, and Simon JA. Vulvovaginal atrophy: Current and future therapies. J Sex Med 2010;7:1042–1050.